ANG Lifesciences India share news and announcements
BSE: 540694Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹34.15.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹43 Cr3,715th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 0.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −22.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −6.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 1.47
- Volume, BSEVolume. Shares traded on the last trading day.
- 3,136
ANG Lifesciences India share news and announcements
374 announcements, routine notices left out, newest first. Page 4 of 8.
Aug 2022
5 Aug · Board meeting
Meeting on 14 Aug 2022: quarterly results
Jul 2022
18 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 015 Jul · Announcement under Regulation 30 (LODR)-Meeting Updates
5 Jul · Results
Details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly <a href="https://www.bseindia.com/stock-share-price/meetings/voting-results/540694 ....1 Jul · Disclosure Of Related Party Transactions For The Half Year Ended 31St March 2022
Jun 2022
13 Jun · Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
5 Jun · Revised Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
2 Jun · Intimation Of Change In Corporate Office Address Of Registrar And Share Transfer Agent ('RTA') Of The Company.
May 2022
23 May · Board meeting
Meeting on 30 May 2022: bonus issue, audited results and increase in authorised capital
Apr 2022
18 Apr · Compliance Certificate Pursuant To Regulation 7(3) Of Securities Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31/03/2022
11 Apr · Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 09 Apr · Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
1 Apr · Announcement Under Reg. 30 Of SEBI LODR- Achieved Standalone Sales In FY 2021-22.
Mar 2022
25 Mar · Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements), Regulation, 2015
21 Mar · Board meeting
Meeting on 29 Mar 20222 Mar · Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Feb 2022
24 Feb · Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
21 Feb · Disclosure Under Reg. 30 Of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015.
7 Feb · Board meeting
Meeting on 14 Feb 2022: quarterly results
Jan 2022
19 Jan · Shareholding for the Period Ended December 31, 2021
Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click ....19 Jan · Disclosure Under Reg. 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015.
14 Jan · Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Dec 2021
1 Dec · Reply Of Email Received From BSE In Regards Of Discrepancies In PDF Of Consolidated Cash Flow Statement For The Half Year Ended As At 30Th September 2021
Nov 2021
23 Nov · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....